Evidence map›Paper›PMID 37756546›Full record

ArticleBlood advances2023

Runx1-R188Q germ line mutation induces inflammation and predisposition to hematologic malignancies in mice.

Mohd Hafiz Ahmad, Mahesh Hegde, Waihay J Wong, Mona Mohammadhosseini, Lisa Garrett, Anneliese Carrascoso, Neethu Issac, Benjamin Ebert, Jeffrey C Silva, German Pihan and 5 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Targeting RUNX1 Germline Variants: Agents Under Investigation.Current hematologic malignancy reports · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Mohd Hafiz AhmadDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA.ORCID 0000-0002-4798-9966
Mahesh HegdeDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA.ORCID 0000-0002-7853-6281
Waihay J WongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-2023-6590
Mona MohammadhosseiniSchool of Medicine Cell and Developmental Biology Graduate Program, Oregon Health Science University, Portland, OR.ORCID 0000-0002-5643-6052
Lisa GarrettTransgenic Mouse Core, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.
Anneliese CarrascosoDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA.
Neethu IssacDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA.ORCID 0000-0003-1645-1925
Benjamin EbertDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-0197-5451
Jeffrey C SilvaAdeptrix Corporation, Beverly, MA.
German PihanDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.ORCID 0000-0003-0183-2477
Lihua J ZhuDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA.ORCID 0000-0001-7416-0590
Scot A WolfeDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA.ORCID 0000-0002-7042-201X
Anupriya AgarwalSchool of Medicine Cell and Developmental Biology Graduate Program, Oregon Health Science University, Portland, OR.ORCID 0000-0002-8319-6162
P Paul LiuOncogenesis and Development Section, Division of Intramural Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-6779-025X
Lucio H CastillaDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA.ORCID 0000-0002-7450-758X
University of Massachusetts Chan Medical School · USDana-Farber Cancer Institute · USNational Institutes of Health · USOregon Health & Science University · US

Funding

Targeted Small Molecule Inhibitors for Inv(16) LeukemiaR01CA234478 · NCI · UNIVERSITY OF VIRGINIA · PI BUSHWELLER, JOHN HACKETT, CASTILLA, LUCIO H. · 2019 to 2023
$3.4M
Inflammation-Driven Clonal Evolution in RUNX1 Carriers: Mechanisms and Therapeutic VulnerabilitiesR01HL155426 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Anupriya Agarwal · 2021 to 2026
$2.7M
The role of inflammation in driving leukemogenesis in germline predisposition syndromesU01CA257666 · NCI · UNIVERSITY OF CHICAGO · PI AGARWAL, ANUPRIYA, BRESNICK, EMERY H. · 2022 to 2025
$2.5M
Mechanisms of inv(16) acute myeloid leukemiaR01CA204979 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CASTILLA, LUCIO H. · 2017 to 2021
$2.1M
NCI NIH HHS R01 CA204979NCI NIH HHS R01 CA234478NCI NIH HHS U01 CA257666NHLBI NIH HHS R01 HL155426
6 · The paper itself

Abstract

Germ line mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). Patients with FPD frequently show clonal expansion of premalignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the premalignant bone marrow (BM) is not well-understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an FPD-associated mutation, Runx1R188Q. Immunophenotypic analysis showed an increase in the number of hematopoietic stem and progenitor cells (HSPCs) in the Runx1R188Q/+ mice. However, the comparison of Sca-1 and CD86 markers suggested that Sca-1 expression may result from systemic inflammation. Cytokine profiling confirmed the dysregulation of interferon-response cytokines in the BM. Furthermore, the expression of CD48, another inflammation-response protein, was also increased in Runx1R188Q/+ HSPCs. The DNA-damage response activity of Runx1R188Q/+ hematopoietic progenitor cells was defective in vitro, suggesting that Runx1R188Q may promote genomic instability. The differentiation of long-term repopulating HSCs was reduced in Runx1R188Q/+ recipient mice. Furthermore, we found that Runx1R188Q/+ HSPCs outcompete their wild-type counterparts in bidirectional repopulation assays, and that the genetic makeup of recipient mice did not significantly affect the clonal dynamics under this setting. Finally, we demonstrate that Runx1R188Q predisposes to HM in cooperation with somatic mutations found in FPDHM, using 3 mouse models. These studies establish a novel murine FPDHM model and demonstrate that germ line Runx1 mutations induce a premalignant phenotype marked by BM inflammation, selective expansion capacity, defective DNA-damage response, and predisposition to HM.

Indexed as

Blood Platelet DisordersHematologic NeoplasmsAnimalsCore Binding Factor Alpha 2 SubunitDisease SusceptibilityDNAGerm-Line MutationHumansInflammationMiceCore Binding Factor Alpha 2 SubunitDNARunx1 protein, mouse

Identifiers

PMID37756546
PMCPMC10711191
OpenAlexW4387088923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.